Calls for papers
-
Bryn Pharma said that it has completed a pivotal study of its Utuly (BRYN-NDS1C) epinephrine nasal spray comparing PK/PD profiles of Utuly to a 0.3 mg dose of epinephrine delivered by autoinjector. According to the… Read more . . .
-
Device maker Nemera has announced the opening of its new headquarters building in Lyons, France. According to the company, the new BREEAM-certified building will also be home to the company’s European innovation teams. Nemera also… Read more . . .
-
According to CanSino Biologics, China’s National Medical Products Administration (NMPA) has approved the company’s Convidecia Air nebulized COVID-19 vaccine as a booster dose. In December 2021, CanSino Bio announced a deal with Aerogen for the… Read more . . .
-
Vistagen Therapeutics has announced that it will restart the Phase 3 PALISADE-2 trial of PH94B aloradine nasal spray for the treatment of anxiety in social anxiety disorder (SAD), which the company had paused after the… Read more . . .
-
According to Bharat Biotech, Indian regulators have cleared its iNCOVACC (BBV154) intranasal vaccine against COVID-19 for use in adults aged 18 and older under a Restricted Use in Emergency Situation. Following the approval, Bharat Bio… Read more . . .
-
FluGen has announced that a Phase 1b age de-escalation clinical trial of its M2SR intranasal live virus flu vaccine has completed enrollment of the first cohort, which includes children aged 9-17. The study will subsequently… Read more . . .
-
Illiad Biotechnologies has closed a $42.8 million financing round, the company said, with the funds intended to support a Phase 2b challenge study of the company’s BPZE1 intranasal pertussis vaccine as well as other development… Read more . . .
-
The FDA has published notice of an online meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to take place on November 8, 2022 for the purpose of discussing Avillion and AstraZeneca’s NDA (214070) for PT027… Read more . . .
-
MannKind Corporation announced today that a Phase 1 study of MNKD-101 clofazimine demonstrated that the inhalation suspension was well tolerated at doses up to 90 mg/day over 7 days and identified no safety issues. The company… Read more . . .
-
Hoth Therapeutics said that a preclinical study conducted at North Carolina State University demonstrated that the company’s HT-004 inhaled antisense oligonucleotide significantly reduced lung inflammation in mice following an ovalalbumin challenge. According to Hoth, HT-004… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland